AgingResearch.NewsJoin free

Phase 1Active, not recruiting

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

An Open-label, Fixed-sequence Study to Assess the Effect of Elecoglipron on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Participants

Sponsor
AstraZeneca (Industry)
Enrolment
48 enrolled
Conditions
Healthy Participants
Interventions
Elecoglipron; Atorvastatin; Rosuvastatin
Ages
adults
Registry
NCT07534592

Full record on ClinicalTrials.gov

From the registry

The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.

Primary outcomes

  • Area under concentration-time curve from time 0 to infinity (AUCinf) of atorvastatin
  • Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of atorvastatin
  • Maximum observed drug concentration (Cmax) of atorvastatin
  • AUCinf of rosuvastatin

History

  1. Primary completion

  2. Last registry update

  3. Registered

  4. Started